Mr. Schwarzer has served as our Chief Executive Officer and a member of our Board of Directors since 2010. Mr. Schwarzer also served as a Managing Partner of Charter Life Sciences, a venture capital firm specializing in life sciences investments, for approximately 15 years. He also served as the Chair of Inviragen, the creators of the DENVax dengue vaccine, from the time of its first venture capital financing until its acquisition by Takeda. He previously served as Chief Executive Officer and then Chair of the Board of Directors of Heska Corporation, a biotechnology company. Mr. Schwarzer received a B.A. in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.
Dr. Chen has served as our Chief Medical Officer since 2018. Dr. Chen joined us from Roche/Genentech, where he served in various research and leadership positions, most recently as Vice President, Global Head of Cancer Immunotherapy since 2006. While at Roche/Genentech, he also served as Cancer Immunotherapy Franchise Head, Product Development and led the development of Tecentriq from entry into first in human studies to multiple global registration approvals. Dr. Chen also serves on the Board of Directors of the Society for Immunotherapy of Cancer and is Co-chair of the Cancer Immunotherapy Committee, an arm of the Cancer Research Institute. Dr. Chen received a B.S. in Biology from the Massachusetts Institute of Technology and an M.D. and Ph.D. from the University of Southern California School of Medicine and Microbiology & Immunology. He completed his residency in internal medicine, a fellowship in Medical Oncology and a post doctorate in Immunology at Stanford University. Dr. Chen ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003 to 2006, where he also cared for melanoma patients and studied human immune responses to cancer vaccination and cytokine administration until 2016.
Dr. Decker has served as our Chief Business Officer since 2021. Prior to joining us, Dr. Decker was Chief Business Officer at Atreca, where she led business development, including portfolio and alliance management functions. Dr. Decker has also served in multiple roles at Nektar Therapeutics, culminating in her final role as Vice President, Business Development, where she led all partnering activities including strategy, identifying and assessing new opportunities and developing deal structures and financial terms. She began her career in business development at the University of Massachusetts Medical School, where she was responsible for licensing, intellectual property strategy and management, and marketing of early stage life science inventions, including the University’s Nobel Prize winning RNAi technology. Dr. Decker received her Ph.D. in Immunology from Tufts University School of Medicine and her B.A. in Biology from the College of the Holy Cross.
Mr. Gauthier has served as our Chief Commercial Officer since 2021. Mr. Gauthier joins IGM with twenty years of experience in global commercial strategy, marketing, sales and product development. Most recently, he was Vice President of Global Product Strategy for Breast and Gynecological Cancers at Genentech, where he led a global team in the creation and execution of commercial and product development strategies. Prior to his most recent role at Genentech, Mr. Gauthier served in multiple other roles at Genentech, including Life Cycle Leader of ROZYLTREK and KADYCLA, where he developed and implemented a new commercial model for rare biomarker driven cancers. Before his time at Genentech, Mr. Gauthier served in a variety of roles at F. Hoffman-La Roche in Switzerland, including as International Business Leader for Tarceva. Mr. Gauthier received his M.B.A. from Kellogg Graduate School of Management at Northwestern University and his B.S. in Chemical Engineering from Michigan State University.
Dr. Keyt has served as our Chief Scientific Officer since 2012, after serving in that role as a consultant for us beginning in 2010. Prior to joining us, Dr. Keyt served as Chief Technology Officer at Trellis Bioscience, an antibody discovery company, from 2007 to 2010. Previously, he served as Head of Research for Abmaxis, a biotechnology company, from 2005 through its acquisition by Merck in 2006. He was also Vice President of Preclinical Development at Abgenix, a biotechnology company, from 2001 through its acquisition by Amgen in 2005. Dr. Keyt was the Director of Pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in various research and leadership roles at Roche/Genentech, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate (Factor VIII). Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry and Pharmacology from Tufts University School of Medicine.
Mr. Tahir has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Tahir was with Dermira, a biotechnology company, where he served in various roles from 2014 to 2018, most recently, as Vice President, Head of Finance. Previously, he held finance and leadership positions at various biotechnology companies, including Onyx Pharmaceuticals, Human Genome Sciences and Amgen. Mr. Tahir began his career as a management consultant at the consulting firm of Oliver Wyman, formerly Mercer Management Consulting. He received a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from the University of Michigan Business School.
Dr. Peterson joined us in 2017 and serves as our Senior Vice President of Process Sciences and Manufacturing. Dr. Peterson also served as Senior Director, Manufacturing at MabVax Therapeutics, a biotechnology company, from 2015 to 2017 and as Senior Director, Upstream Process Development and Manufacturing at Ambrx, a biotechnology company, from 2014 to 2015. Dr. Peterson has also served in manufacturing, scientific and leadership positions at Bristol-Myers Squibb, Eli Lilly, Celgene and Shire. He received a B.S. in Chemical Engineering from the University of Colorado, Boulder and a Ph.D. in Chemical Engineering from Purdue University. Dr. Peterson also completed a post doctorate at the University of Minnesota, BioProcess Technology Institute.
Dr. Carroll has served as our Vice President of Preclinical Sciences since 2015, after having served as a consultant for us beginning in 2013. Previously, Dr. Carroll spent 17 years in various scientific and leadership positions at Xoma, a biotechnology company, including Vice President of Preclinical Research and Scientific and Product Development. He received a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Microbiology from the University of California, Los Angeles. Dr. Carroll also completed a post doctorate in Microbiology at the University of California, Los Angeles, and he was an Assistant Professor in the Department of Microbiology and Molecular Genetics at Harvard Medical School.
Dr. Godfrey has served as our Vice President of Clinical Development since 2018. Prior to joining us, Dr. Godfrey served as Senior Director, Clinical Development at Kite Pharma, a biotechnology company and subsidiary of Gilead, from 2017 to 2018. Dr. Godfrey also served as Chief Medical Officer at Etubics, a biotechnology company, from 2015 to 2016, and as Senior Director, Clinical Research Oncology at Gilead from 2012 to 2015. He received a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Barbara, an M.S. in Biology from Stanford University and an M.D. from Washington University School of Medicine in St. Louis. Dr. Godfrey completed his internal medicine residency and clinical immunology, hematology and bone marrow transplantation fellowships at Stanford University.
Mr. Graffagnino has served as our Vice President of Legal Affairs since 2021. Mr. Graffagnino spent over two decades in private legal practice in Silicon Valley providing corporate and securities advice to technology companies as a Partner at the law firm of GCA Law Partners LLP. He began his legal career as an Associate in the Washington, D.C. office of Skadden Arps Slate Meagher & Flom LLP and became a Partner in the San Francisco office of Pillsbury Winthrop Shaw Pittman LLP. Mr. Graffagnino received a B.A. in Political Economy from Williams College and a J.D. from Georgetown University Law Center.
Dr. Haanes has served as our Vice President of Intellectual Property since 2019. Dr. Haanes spent the past 19 years in private legal practice in the Washington D.C. area, providing intellectual property services to a broad spectrum of biotechnology and pharmaceutical companies. Most recently she practiced as a Partner at the law firm of FisherBroyles, LLP, and prior to that was a Partner at Thompson Coburn LLP and a Director at Sterne Kessler Goldstein & Fox, PLLC. Prior to entering law school, Dr. Haanes conducted virology research as a scientist at Heska Corporation. Dr. Haanes received a B.S. in Biology from the University of Michigan, a Ph.D. in Microbiology from the University of Minnesota, and a J.D. from the University of Colorado.
Mr. Harigopal has served as our Vice President of Information Technology since 2021. Prior to IGM, he served as Senior Director of IT at Cytokinetics, a public biotech focused on cardiovascular and neuromuscular diseases, where he led IT business solutions. Prior to Cytokinetics, he was Director of IT at Pharmacyclics, a public, commercial-stage biotech acquired by AbbVie, where he led enterprise business applications and web-mobile technologies. TS also spent nearly 12 years at Johnson & Johnson’s medical devices division, Lifescan, where he held IT roles of increasing responsibility in both the U.S. and Europe. TS holds an M.B.A. from California State University, East Bay and a Bachelor’s degree in Finance and Commerce from the University of Bombay, India
Dr. Humke has served as our Vice President of Clinical Development, Apoptosis since 2019. Prior to joining us, Dr. Humke was Senior Medical Director at Genentech in Research & Early Clinical Development where he led numerous clinical programs evaluating antibody drug conjugates for multiple myeloma, lung, ovarian, and endometrial cancer. He also oversaw multiple small molecule inhibitor programs for multiple myeloma, lung and breast cancer. Prior to joining Genentech, he was an Instructor of Medicine in the Division of Oncology at the Stanford University School of Medicine where he conducted research and clinical studies from 2009-2011. Dr. Humke received a B.S. at Brown University and an M.D., Ph.D. from the University of Michigan. Dr. Humke completed his internal medicine residency at Washington University in St. Louis (Barnes-Jewish Hospital) and a medical oncology fellowship at Stanford University.
Dr. Miller has served as our Vice President of Antibody Discovery since April 2020. Prior to joining us, Dr. Miller served as Vice President, Biotherapeutics at Five Prime Therapeutics, a biotechnology company, from 2015-2020. She has also served in various scientific and leadership roles at Novartis Institutes for Biomedical Research, and at Merck Research Laboratories at the former DNAX/Schering Plough site. Dr. Miller has broad experience in discovering and developing biologic formats including antibody, bispecific antibody, fusion protein, and ADC, with therapeutic focus in oncology, autoimmunity, and immuno-oncology. Dr. Miller received a B.S. and a Ph.D. in Molecular Genetics from The Ohio State University, and completed a post doctorate at Genentech.
Dr. Sinclair has served as our Vice President of Immuno-oncology since 2018. Prior to joining us, Dr. Sinclair served as Senior Director, Oncology Research at Northern Biologics, a biotechnology company, from 2015 to 2018. He also previously served in various scientific and leadership positions at Amgen, including most recently as Scientific Director, Oncology Research, from 2011 to 2015. Dr. Sinclair received a B.Sc. in Molecular Biology from the University of Edinburgh and a Ph.D. in Hematology/Molecular Biology from the National Institute for Medical Research/University College London.
Ms. Tauber has served as our Vice President of Human Resources since 2019. Prior to joining us, Ms. Tauber was in charge of human resources at ARMO BioSciences, a biotechnology company, from before its initial public offering through its acquisition by Eli Lilly. Previously, she held human resources leadership positions at a variety of life science and high-technology companies, including Cellular Research (acquired by Becton Dickinson), Kapor Enterprises, Escalate, KIVA Software (acquired by Netscape/AOL) and Bay Networks (acquired by Nortel). Ms. Tauber’s career in human resources began with Bain & Company, where she led their West Coast recruiting efforts. She received a B.A. in Communications from Northern Arizona University.